header logo image


Page 30«..1020..29303132..4050..»

Archive for the ‘Diabetes’ Category

Nutritional and Dietary Requirements in Patients with Type 2 Diabetes and CKD – DocWire News

Monday, March 9th, 2020

There is a significant correlation between type 2 diabetes mellitus and chronic kidney disease (CKD); up to 40% of patients with diabetes develop CKD as a direct result of diabetic complications. Patients with CKD have a need for a disease-specific diet, making management of diabetes challenging. Patients with CKD also face increased risk of complications associated with malnutrition, necessitating dietary needs and nutritional requirements tailored to individual patients.

Researchers led by Nourhan Khaled Hassan, MD, recently conducted a systematic review to examine nutritional requirements for patients with type 2 diabetes and chronic renal failure. The researchers screened 85 articles; of those, 22 were analyzed and included as per the study criteria. The data search included PubMed using medical subject headings terms, and a literature review through the Cochrane library and the British Medical Journal. Results were reported online in Current Diabetes Reviews [doi:10.2174/15733998166662000211120402].

The review highlighted nutrients and minerals needed to be maintained within a specified range defined by a patients needs and conditions. Dietary restrictions to prevent disease progression were also necessary. Patients receiving hemodialysis required vigorous monitoring of blood glucose levels as well as strict management of dietary intake. Risk-to-benefit ratios were utilized to determine optimal protein intake in patients on hemodialysis.

Dietary requirements should be individualized based on the patients disease severity and progression. Assessment of the patients previous and current diet, as well as matching it with their dietary requirements and preferences is crucial, the researchers said.

Read more from the original source:
Nutritional and Dietary Requirements in Patients with Type 2 Diabetes and CKD - DocWire News

Read More...

Diabetes and Cardiovascular Disease Mortality Among A Population-Based Cohort of Women with and Without Breast Cancer – DocWire News

Monday, March 9th, 2020

PURPOSE:

We investigated whether the relationship between diabetes and all-cause and CVD-related mortality differed between women with and withoutbreast canceramong a cohort drawn from the same source population.

We interviewed 1,363 women newly diagnosed withbreast cancerin 1996-1997, and 1,358 age-matched women withoutbreast cancer, to assess history of physician-diagnosed diabetes. All-cause (n=631) and CVD-specific mortality (n=234) was determined by the National Death Index through 2009. We estimated multivariable-adjusted hazard ratios (HRs) for the rates of all-cause and CVD-specific mortality and, to account for competing causes of death, and subdistribution HRs (sHRs) for risk of CVD-related death.

Among women with and withoutbreast cancer, respectively, diabetes was associated with: all-cause mortality [HR (95% CI) 1.52 (1.13, 2.05) and 2.17 (1.46, 3.22)]; CVD-specific deaths [1.74 (1.06, 2.84) and 2.06 (1.11, 3.84)]; and risk of CVD-related death [sHR 1.36 (0.81, 2.27) and 1.79 (0.94, 3.40)]. Differences in effect estimates between women with and withoutbreast cancerdid not reach statistical significance (p-interaction>0.10).

We found that the positive association between a history of physician-diagnosed diabetes and risk of all-cause and CVD-related mortality is of similar magnitude among a population-based cohort of women with or withoutbreast cancer.

Go here to see the original:
Diabetes and Cardiovascular Disease Mortality Among A Population-Based Cohort of Women with and Without Breast Cancer - DocWire News

Read More...

Gut microbiota composition tied to type 2 diabetes remission following bariatric surgery in obese diabetic women – Gut Microbiota for Health

Monday, March 9th, 2020

Research over the last decade has considered the potential role of gut microbiota in the development of obesity and its related metabolic disorders. Although initial findings in mice showing the relevant contribution of gut microbiota to weight change have not been translated in a straightforward way in humans, scientists hypothesize that gut microbes may help us understand the effectiveness of weight-loss strategies such as diet and bariatric surgery.

Kaplans group experiments in mice were among the first to find that changes in gut microbiota composition could account for some of the weight loss that happens after a gastric bypass. Although it seems microbes work by allowing animals to burn more energy, how exactly an altered intestinal microbiota might cause weight loss and metabolic improvements remains to be seen.

New research in obese diabetic women shows that gut microbiota composition before Roux-en-Y gastric bypass is linked to postoperative type 2 diabetes remission.

The authors sought to explore to what extent metabolic benefits after Roux-en-Y gastric bypass (RYGB) are related to gut microbiota profile in obese diabetic women.

Anthropometric and body composition variables improved up until 12 months after surgery. More interestingly, preoperative gut bacteria composition at the genus level differed between patients with and without T2D remission after surgery (57% versus 43%). Total type 2 diabetes remission after RYGB (assessed according to American Diabetes Association criteria) was associated with specific gut microbiota signatures before surgery. Those microbiota changes consisted of lower levels of Asaccharobacter and Atopobium and higher levels of Gemella, Coprococcus, and Desulfovibrio.

Specifically, the preoperative abundance of 10 gut bacteria genera correlated with the type 2 diabetes remission status, showing good sensitivity and specificity.

According to Karina Al Assal, one of the studys lead authors, These findings show that we can predict who is going to remit T2D before the surgery using the gut microbiota profile as a biomarker. This signature, if confirmed, may enable the prediction of future remission state of T2DM.

By contrast, postoperative changes in the relative abundance of gut bacteria and their richness were observed regardless of whether participants showed T2D remission or not.

The authors also reported some correlations between gut microbiota richness (defined as the number of species in fecal samples, without taking into account the abundance of each one) and food intake based on a 7-day record. For instance, before surgery, gut microbiota richness showed a positive correlation with fiber intake and inverse association with lipid intake, with the latter persisting until 12 months after surgery.

Although limited in sample and despite the quasi-experimental design of the study, these findings show that improvements in body and metabolic parameters secondary to RYGB surgery may be partly explained by gut microbiota composition.

Regarding how these findings might impact on clinically managing obesity in the foreseeable future, Karina Al Assal highlighted to GMFH editors via email that the study of gut bacteria signatures at the preoperative period in obese patients might pave the way for using gut microbiota as a marker to help clinicians when deciding on whether to recommend bariatric surgery. Likewise, based on associations found between gut bacteria and food intake, adding fibers and reducing lipid intake might improve the outcome of bariatric surgery.

Reference:

Al Assal K, Prifti E, Belda E, et al. Gut microbiota profile of obese diabetic women submitted to Roux-en-Y gastric bypass and its association with food intake and postoperative diabetes remission. Nutrients. 2020; 12, 278. doi: 10.3390/nu1202278.

Read the original:
Gut microbiota composition tied to type 2 diabetes remission following bariatric surgery in obese diabetic women - Gut Microbiota for Health

Read More...

Efficacy of Zotarolimus-Eluting Stents in Treating Diabetic Coronary Lesions: An Optical Coherence Tomography Study. – Physician’s Weekly

Monday, March 9th, 2020

Diabetes mellitus (DM) plays an important role in restenosis and late in-stent thrombosis (ST).The current study using optical coherence tomography (OCT) aims to compare target lesion neointima in patients with or without diabetes after zotarolimus-eluting stent (ZES) treatment.OCT images of 90,212 struts and quantitative coronary angiography (QCA) in 62 patients (32 with DM and 30 without DM) with 69 de novo coronary lesions (34 DM and 35 non-DM) both after ZES implantation and 121month angiographic follow-up were recorded. Patient characteristics, lesion characteristics, clinical outcomes, and OCT findings including neointimal thickness, coverage, malapposition, and intimal morphology were analyzed.Baseline patient characteristics and lesion characteristics data were similar between the two groups. Higher neointimal thickness (0.140.09mm vs. 0.090.04mm, p=0.021), more neovascularization (3.036.24 vs. 0.521.87, p=0.017) and higher incidence of layered signal pattern (12.1919.91% vs. 4.289.02%, p=0.049) were observed in diabetic lesions comparing with non-diabetic lesions. No differences were found in malapposition, uncovered percentage, and thrombus between the two groups (all p>0.05). Occurrence of clinical adverse events was also similar during the follow-up period (p>0.05).Although more neointimal proliferation and more neovascularization were found in diabetic coronary lesions whencompared with non-diabetic lesions, treatment with ZES showed similar stent malapposition rate at 1-year follow-up. The data indicated that ZES treatment could possibly beeffective in treating diabetic coronary lesions.ClinicalTrials.gov identifier, NCT01747356.

Here is the original post:
Efficacy of Zotarolimus-Eluting Stents in Treating Diabetic Coronary Lesions: An Optical Coherence Tomography Study. - Physician's Weekly

Read More...

Diabetic Care Market by Type (Youth Onset Diabetes, Adult Onset Diabetes, and Gestational Diabetes), By End-User (Research Institute, Hospital, and…

Monday, March 9th, 2020

The report on Diabetic Care Market offers an in-depth analysis of market trends, drivers, restraints, opportunities, etc. Along with qualitative information, this report comprises the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global Diabetic Care Market is segmented on the basis of type, application, and geography.

The report researches into the Diabetic Care market to evaluate its current and future potential. It leverages historical statistics about the Diabetic Care market, data from various other websites and sources, and inputs by the experts of the industry. It focuses completely on analyzing the regional subdivisions of the Diabetic Care markets.

Global Diabetic Care market is estimated to reach $112.2 Million by 2025; growing at a CAGR of 6.23% till 2025.

Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority): https://www.esticastresearch.com/report/global-diabetic-care-market/#request-for-sample

Competitive Landscape

Key Players in this showcase are:

AstraZeneca Pharmaceuticals LPBristol-Myers Squibb CoDexcom, Inc.Eli Lily and CompanyJohnson & Johnson Services, Inc.MedtronicNovo Nordisk A/SRoche Diagnostics LtdSanofi S.A.Terumo Europe NV

Diabetic Care showcasing different procedures and strategies, providers and merchants working in the Diabetic Care market, investigates components convincing Diabetic Care market development, generation patterns, and following systems. The overall Diabetic Care market report performs SWOT examination and PESTEL Diabetic Care investigation to uncover the steadiness, imperfections, openings, and dangers in the Diabetic Care industry. Moreover, it thinks about the earlier years information to see the deterrents looked by new players in the Diabetic Care market universally, the danger from other administrations or items, and the general showcase limit of the aggressive players.

Global Diabetic Care Market Segmentation:

The Diabetic Care Market report also covers segment analysis, including product type, application, and region, etc. cover different segment market sizes, both volume, and value.

Global Diabetic Care market segmentation:

By Type

Youth Onset DiabetesAdult Onset DiabetesGestational DiabetesBy End-User

Research InstituteHospitalHome Care

Click to access full report andTable of Content and Figures @ https://www.esticastresearch.com/report/global-diabetic-care-market/#table-of-content

Global Diabetic Care market segmentation by Geography:

The estimates for all segments including type and application have been provided on a regional basis for the forecast period mentioned above. We have implemented a mix of top-down and bottom-up approaches for market sizing, analyzing the key regional markets, dynamics, and trends for various applications. The Global Diabetic Care market has been estimated by integrating the regional markets.

Latitude of the Diabetic Care Market report is as follows:

Request Customization or Discount of This Report @ https://www.esticastresearch.com/report/global-diabetic-care-market/#customization

Reasons to buy Diabetic Care Market Report:

Esticast Research is a research firm providing research reports on various industries with a unique combination of authenticity, extensive research, and infallibility. We provide syndicated market research reports, customization services, and consulting services to help businesses across the world in achieving their goals and overcoming complex challenges. We specialize in providing 360 degree view of the markets to assist clients in determining new opportunities and develop business strategies for the future with data and statistics on changing market dynamics. Esticast Research & Consulting has expert analysts and consultants with an ability to work in collaboration with clients to meet their business needs and give opportunities to thrive in a competitive world. A comprehensive analysis of industries ranging from healthcare to consumer goods and ICT to BFSI is provided by covering hundreds of industry segments. The research reports offering market forecasts, market entry strategies, and customer intelligence will help clients across the world in harnessing maximum value on their investment and realize their optimum potential..

Get In Touch!Esticast ResearchNavale ICON IT Park,Office No. 407, Mumbai Bangalore Highway, Narhe, PuneUSA:+1-213-275-4706IND+91-844-601-6060Email:[emailprotected]

See the article here:
Diabetic Care Market by Type (Youth Onset Diabetes, Adult Onset Diabetes, and Gestational Diabetes), By End-User (Research Institute, Hospital, and...

Read More...

More than $700K to go toward type 1 diabetes research – Concord Monitor

Monday, March 9th, 2020

Published: 3/8/2020 6:31:19 PM

Nearly $713,000 in federal funding is going to Dartmouth College to support research to test new ways to better treat and control type 1 diabetes.

The funding will go toward a five-year study that will use digital tools to support behavioral changes to help young people with diabetes follow a complicated medical regimen and achieve better health outcomes.

It will be distributed by the National Institute of Diabetes and Digestive and Kidney Diseases, which is part of the National Institutes of Health.

The funding was announced recently by New Hampshires congressional delegation.

Research like this can help to improve quality of life and, ultimately, medical outcomes for countless patients, U.S. Sen. Maggie Hassan said in a statement.

The funding to Dartmouths Center for Technology and Behavioral Health will go toward a study led by Dr. Catherine Stanger.

I am grateful to the NIH for their support of this work since 2012, and look forward to leading this national project, where we will reach out directly to young adults with type 1 diabetes to support them in learning to better manage this complex and challenging condition, said Stanger said.

Associated Press

See the original post here:
More than $700K to go toward type 1 diabetes research - Concord Monitor

Read More...

Reverse symptoms of diabetic neuropathy with life-changing treatment – KHOU.com

Monday, March 9th, 2020

HOUSTON Pain, numbness and tingling in your hands and feet can be a sign you have neuropathy or nerve damage. Common treatments include pain medication, injections, or tens (an electrical stimulator), but Dr. Bao Thai from Advanced Nerve and Health Center says these treatments aren't effective for neuropathy.

Dr. Thai has developed a non-invasive, pain free treatment that helps the body repair nerves without surgery or medication. Patients are seeing amazing results.

Dr. Thai is a pioneer in this field, and has studied all over the world exploring technologies and processes. Through his own research, he found the body wants to heal the nerve, and over time it will heal.

The Advanced Nerve and Health Center has a limited time offer for Great Day Houston viewers. For $27, the first 17 callers will get an in-office consultation, a copy of Dr. Thai's "Healthy Diet to Heal Nerve Pain" book, and a diagnostic nerve test to see if they can help. This is a $399 value.

Call Advanced Nerve and Health Center now at 832-626-1260.

Advanced Nerve and Health Center is located at 8558 Katy Freeway, Suite 116, Houston, TX 77024.

For more information, log on to NerveAndHealth.com.

This content is sponsored by: Advanced Nerve and Health Center

See the rest here:
Reverse symptoms of diabetic neuropathy with life-changing treatment - KHOU.com

Read More...

The underlying health conditions which affect how you cope with the coronavirus – Telegraph.co.uk

Monday, March 9th, 2020

As the number of UK cases of coronavirus continues to rise, what has become clear is how many of the patients to die from the virus have underlying health conditions that make them susceptible to catching it.

Thethird person in the UK to die, after testing positive for the coronavirus upon his return from Italy, was being treated at the North Manchester General Hospital for underlying health conditions when he died.

The UKs second death was a man in his early 80s, who also had underlying health issues, as did the woman in her 70s who became the UKs first death linked to the virus.

Its a new infection, but from our experience with dealing with flu epidemics, we know that people with various conditions will fare worse, says Fan Chung, a professor of respiratory medicine at Imperial College. A paper has just published in the New England Journal of Medicine, that looked at the first 1,001 cases in Wuhan. The figures showed those with diabetes, high blood pressure, heart disease, COPD, cancer and renal disease, fared worse. And I suspect the people who very unfortunately died in the UK had one or any of those conditions."

A Chinese study hasfound people with heart disease, diabetes and cancer had a 79 per cent chance of being admitted to intensive care or dying from the virus, due to their weakened immune systems.

Here are the underlying health conditions that put you at higher risk of getting the coronavirus a reminder of how it might initially spread.

People with diabetes face a higher risk of complications if they get the coronavirus, due to the fact their fluctuating or elevated glucose levels leave them with lowered immunity. This also means they have less protection against getting the virus. Coronavirus or COVID-19 can cause more severe symptoms and complications in people with diabetes, says Dan Howarth from Diabetes UK. If you have diabetes and you have symptoms such as a cough, high temperature and feeling short of breath you need to monitor your blood sugar closely and call the NHS 111 phone service.

People with diabetes who dont experience symptoms and have recently travelled to any of the affected areas need to follow information on the NHS and theGOV.UKwebsites, adds Howarth. "These are updated regularly and are the most up-to-date source of information available.

Its believed around 40 per cent of hospitalised coronavirus patients have heart disease. Somebody with a heart condition is more likely to have a compromised immune system, so their immune response wont be as strong if exposed to a virus. COVID-19 also targets the lungs, which could cause problems for a diseased heart that has to work harder to get oxygenated blood around the body.

Asthma is a respiratory condition that leads to inflammation of the breathing tubes that transport air to and from the lungs.Coronavirus can cause respiratory problems for anyone, but for the 5.4million people in the UK with asthma, the risk is greater, says Jessica Kirby, Head of Health Advice at Asthma UK. Respiratory viruses like thiscan triggerasthma symptoms and couldlead to anasthma attack.

Kirby says if youre a sufferer, itsessential to takeyour preventer, daily as prescribed. This helps cut the risk of an asthma attack being triggered by any virus, including coronavirus, she says. Keeping a reliever inhaler to handis vital, soyoucan use it ifyou get asthmasymptoms.

Ifyourasthma symptomsgetworse, and you havent travelled to an at-risk area or been in contact with someone who has, make an appointment to see your GP as soon as you can. If you think you might have coronavirus, use the NHS 111 online coronavirus service."

COPD is the name for certain lung conditions that cause breathing difficulties, including emphysema, which is characterised by damage to the air sacs in the lungs,and chronic bronchitis, which is a long-term condition involving inflammation of the lungs airways. People with COPD are more likely to get coronavirus if exposed to the virus because they have damage to their epithelial lining, which makes it easier for viruses to enter the body.

Cancer patients are more susceptible due to their compromised immune system. Various cancer drugs and treatments, like chemotherapy, mean your immune system may be suppressed, says Prof Chung, and this would increase your chances of catching it. And if you do get it while you havecancer, you would probably fare worse than somebody with the virus who didnt have cancer.

Not a health condition as such, but many of the thousands of deaths so far have involved elderly people with underlying health conditions. The elderly are at greater risk, and government advice for the elderly to avoid crowded areas is sound advice, says Prof Chung. The figures we have so far seem to imply the risk increases above the age of 70. However its even worse for those over 80. The chances of getting it and faring worse increase two or three times above the age the 70, but even more so above 80.

In terms of children, who appear to be less prone to getting the coronavirus and, if they do, getting a more benign version of the illness, Prof Chung says that a young person with an underlying health condition isn't at a greater risk: A young person with asthma, or heart disease, wouldnt be predisposed to get the coronavirusor suffer from it, in the same way an adult with the condition would, he says. Maybe its their immune system, and how its different from older people, but in terms of their susceptibility of getting the coronavirus, health conditions in young people dont seem to increase their chances of catching it.

Read the original here:
The underlying health conditions which affect how you cope with the coronavirus - Telegraph.co.uk

Read More...

Diabetes – World Health Organization

Saturday, March 7th, 2020

What is diabetes?

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood sugar. Hyperglycaemia, or raised blood sugar, is a common effect of uncontrolled diabetes and over time leads to serious damage to many of the body's systems, especially the nerves and blood vessels.

In 2014, 8.5% of adults aged 18 years and older had diabetes. In 2016, diabetes was the direct cause of 1.6 million deaths and in 2012 high blood glucose was the cause of another 2.2 million deaths.

Type 1 diabetes (previously known as insulin-dependent, juvenile or childhood-onset) is characterized by deficient insulin production and requires daily administration of insulin. The cause of type 1 diabetes is not known and it is not preventable with current knowledge.

Symptoms include excessive excretion of urine (polyuria), thirst (polydipsia), constant hunger, weight loss, vision changes, and fatigue. These symptoms may occur suddenly.

Type 2 diabetes (formerly called non-insulin-dependent, or adult-onset) results from the bodys ineffective use of insulin. Type 2 diabetes comprises the majority of people with diabetes around the world, and is largely the result of excess body weight and physical inactivity.

Symptoms may be similar to those of type 1 diabetes, but are often less marked. As a result, the disease may be diagnosed several years after onset, once complications have already arisen.

Until recently, this type of diabetes was seen only in adults but it is now also occurring increasingly frequently in children.

Gestational diabetes is hyperglycaemia with blood glucose values above normal but below those diagnostic of diabetes, occurring during pregnancy.

Women with gestational diabetes are at an increased risk of complications during pregnancy and at delivery. They and their children are also at increased risk of type 2 diabetes in the future.

Gestational diabetes is diagnosed through prenatal screening, rather than through reported symptoms.

Impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG) are intermediate conditions in the transition between normality and diabetes. People with IGT or IFG are at high risk of progressing to type 2 diabetes, although this is not inevitable.

Over time, diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves.

Simple lifestyle measures have been shown to be effective in preventing or delaying the onset of type 2 diabetes. To help prevent type 2 diabetes and its complications, people should:

Early diagnosis can be accomplished through relatively inexpensive testing of blood sugar.

Treatment of diabetes involves diet and physical activity along with lowering blood glucose and the levels of other known risk factors that damage blood vessels. Tobacco use cessation is also important to avoid complications.

Interventions that are both cost-saving and feasible in developing countries include:

Other cost saving interventions include:

WHO aims to stimulate and support the adoption of effective measures for the surveillance, prevention and control of diabetes and its complications, particularly in low and middle-income countries. To this end, WHO:

The WHO "Global report on diabetes" provides an overview of the diabetes burden, the interventions available to prevent and manage diabetes, and recommendations for governments, individuals, the civil society and the private sector.

The WHO "Global strategy on diet, physical activity and health" complements WHO's diabetes work by focusing on population-wide approaches to promote healthy diet and regular physical activity, thereby reducing the growing global problem of overweight people and obesity.

* Defined as fasting blood glucose equal to or higher than 7 mmol/L, or on medication for raised blood glucose, or with a history of diagnosis of diabetes.

** High blood glucose is defined as a distribution of fasting plasma glucose in a population that is higher than the theoretical distribution that would minimize risks to health (derived from epidemiological studies). High blood glucose is a statistical concept, not a clinical or diagnostic category.

(1) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Emerging Risk Factors Collaboration.

Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio et al. Lancet. 2010; 26;375:2215-2222.

(2) Causes of vision loss worldwide, 1990-2010: a systematic analysis.Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H et al. Lancet Global Health 2013;1:e339-e349

(3) 2014 USRDS annual data report: Epidemiology of kidney disease in the United States.United States Renal Data System. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014:188210.

Read this article:
Diabetes - World Health Organization

Read More...

Eating oranges may be the key to losing weight, study finds – Yahoo News

Saturday, March 7th, 2020

Oranges could be great for losing weight, study suggests (Getty Images)

Eating oranges could be the route to losing weight, staying slim and preventing diabetes, new research has found.

This works due to a chemical found in oranges and tangerines called nobiletin.

Nobiletin may even have the ability to reverse obesity and unclog arteries.

In the experiment by the University of Western Ontario, mice were fed the substance and turned out to be leaner and healthier as a result.

The researchers are now conducting the same experiment using humans.

Read more: Waist circumference is vital sign and should be measured

Dr Murray Huff, who has been studying nobiletin's effects for over a decade, was pleased with the research.

We've shown that in mice that already have all the negative symptoms of obesity, we can use nobelitin to reverse those symptoms, and even start to regress plaque build-up in the arteries, known as atherosclerosis.

This means that nobelitin could be essential in reversing symptoms of obesity in its tracks.

How this super compound works is still shrouded in mystery, though.

The researchers originally thought the molecule was likely acting on the pathway that regulates how fat is handled in the body, called AMP Kinase.

This enzyme turns on the machinery in the body that burns fats to create energy, and it also blocks the manufacture of fats.

However, during further tests on mice without AMP Kinase, the nobiletin still had a positive affect.

Read more: Four in five children arent exercising enough, WHO finds

While the way nobiletin is working in the body remains a mystery, Dr Huff was pleased that it didnt work through AMP Kinase.

It shows that nobiletin won't interfere with other drugs that act on the AMP Kinase system, which currently include diabetes medicines like metformin.

The team will now move onto trialling this on human beings.

If its successful, this could provide us with a beneficial way to tackle obesity - a major burden to the healthcare system.

Obesity and its resulting metabolic syndromes are a huge burden to our health care system, and we have very few interventions that have been shown to work effectively.

We need to continue this emphasis on the discovery of new therapeutics.

The rest is here:
Eating oranges may be the key to losing weight, study finds - Yahoo News

Read More...

Diabetes Health Type 1: Food Additives Linked to Rise in Autoimmune Diseases – Diabetes Health

Saturday, March 7th, 2020

By Tanya Caylor

Type 1 diabetes is increasing at a rate of 3 percent per year. Cases of rheumatoid arthritis are rising only slightly less quickly, at least among women, at a rate of 2.5 percent per year. Celiac disease is four times more common now than half a century ago.

What do these statistics have in common? All three are part of an overall increase in autoimmune disorders, which now affect more than 23 million Americans and rank as the third most common type of chronic illness, surpassed only by heart disease and cancer. Scientists have identified at least 80 distinct types of disease in which the body seemingly turns on itself, attacking its own tissue. While the three mentioned above are among the most common, researchers suspect there may be dozens more yet to be discovered.

Though the exact cause of autoimmune disease, in all its many forms, remains unknown, it is suspected that a virus or something in the patients environment interacts with a susceptible set of genes to generate an immunological false alarm. Diet has come under increasing scrutiny in recent years. Some studies on type 1 diabetes, for instance, indicate that a Vitamin D deficiency may be involved, while others point to cows milk products in infancy as playing a possible role. The natural food additive carrageenan, derived from seaweed and increasingly used as a thickening agent in some dairy products, has been linked to an increase in the presence of glycosaminoglycans in the body. A 2015 study suggested these naturally occurring complex carbohydrates may be connected to rheumatoid arthritis. The additive is also under scrutiny by the National Institutes of Health for causing gastrointestinal inflammation potentially related to multiple autoimmune disorders. Both carrageenan and gluten, the protein found in wheat and barley that appears to trigger Celiac disease, are among seven types of food additives that have been linked to an overall increase in autoimmune diseases.

A study published in the June 2015 issue of the journal Autoimmune Reviews singles out sodium, glucose, gluten, emulsifiers (such as carrageenan), organic solvents (such as benzene and hexane), nanometric particles and microbial transglutaminase (an enzyme that acts as a protein glue) as increasing susceptibility to autoimmune diseases by damaging the protective barrier in the bowels designed to keep harmful toxins and bacteria out of the bloodstream.

Note that not all of the food additives are industrial in nature. Sugar and salt, for instance, are common ingredients in foods prepared at home. However, even in their most familiar form, sugar and salt help to increase food absorption. Both can take on more industrialized forms in factory-processed foods. And both have been shown, along with the other additives on the list, to increase intestinal permeability resulting in entry of foreign immunological antigens and activation of the autoimmune cascade.

Getting Past the Bodys Defenses

Noting that only a single layer of epithelial cells separates the luminal contents of the intestine from the effector immune cells, the authors detail literally dozens of biochemical stratagems for getting over, under, around and through the intercellular tight junction, a complex network of proteins that modulate movement of fluid, macromolecules and leukocytes from intestinal lumen to the bloodstream and vice versa. Though these potential breaches are collectively known in laymans terms as leaky gut, in some cases what happens is literally a case of reconfiguring the cellular structure of the sentries on duty.

Of most concern, perhaps, is the least predictable category of additive, known as nanometric particles. Initially used in the pharmaceutical industry as encapsulation devices designed to speed drug delivery into the bloodstream, they are increasingly being used in the food industry to enhance the taste and texture of foods. Trouble is, the rules of operation at the nanotechnology level are not well understood.

If an additives absorption into the body is increased substantially by encapsulating it within lipid nanoparticles, then it could exhibit toxic effects that could not be predicted from data obtained on the same material in microscopic or macroscopic form, write the authors, Dr. Aaron Lerner of the Technion-Israel Institute of Technology and Dr. Torsten Matthias of the Aesku-Kipp Institute in Germany. This is particularly true, they note, if the bioactive component is incorporated into a product that is consumed regularly in large volumes, such as artificially enhanced soft drinks or beverages.

In this study each food additive was studied separately using tissue samples in a lab setting. But in reality the interactions between the modern food supply and the human body is much more complex, the authors note, since in nanotechnology many of the additives can be combined.

The diet of the industrialized world is vastly different from what it was even a generation ago, write Lerner and Matthias, with new genetic modifications, chemical ingredients, flavors, preservatives and new nanotechnologies. Over recent decades, a significant increase in the incidence of autoimmune diseases in industrialized countries has led to the postulation that diet is a potential environmental risk factor for such disorders. Although causality has not been proven, increases in the usage of the abovementioned food additives have paralleled increased incidences of autoimmune diseases over the same amount of time.New Diagnostic Tools for An Evolving Dietary Universe

With changes occurring so quickly in the food industry, health professionals can have a hard time dispensing dietary advice. Even when patients have been advised what to look for, knowing what additives lurk in common foods may be increasingly tricky. Take microbial transglutaminase, the so-called meat glue that can turn random hunks of meat into what appears to be steak. According to the USDA, this enzyme is supposed to appear on the ingredient list of meat products, with the term formed meat product appearing on the label. But if meat glue is used in a restaurant or cafeteria which is increasingly the case customers would have a much harder time knowing what exactly they are cutting into.

Another problem facing modern health care professionals is the increasing evidence of overlap between autoimmune disorders. Though specific diseases have traditionally been treated by doctors who specialize in a particular branch of anatomy, the autoimmune cascade can ultimately entangle multiple systems within the body.

Visit link:
Diabetes Health Type 1: Food Additives Linked to Rise in Autoimmune Diseases - Diabetes Health

Read More...

Organisations partner with Shropshire health groups to prevent type two diabetes – shropshirestar.com

Saturday, March 7th, 2020

Liva Healthcare and Living Well Taking Control (LWTC) have won the contracts with Shropshire and Telford & Wrekin Clinical Commissioning Groups as part of the Healthier You: NHS Diabetes Prevention Programme (NHS DPP).

Liva Healthcare will offer a digital service to complement LWTCs face-to-face intervention programme.

Type two diabetes is one of the most significant healthcare challenges of our time.

There is strong evidence that its onset can be prevented with an improved diet, an increase in physical activity and successful weight loss.

The Healthier You programme was officially launched in 2016 to support people who have a high risk of developing type two diabetes.

The national roll-out of the NHS DPP programme over the last year has seen face-to-face providers supported by digital partners.

The service from Liva Healthcare and LWTC will be provided free of charge to patients at risk of type two diabetes through a referral from their GP.

About 5,000 patients are expected to be treated across Shropshire, Telford and Wrekin, and Dorset through it latest partnership, over the course of a year.

Liva Healthcare provides patients with access to a free, dedicated, personal health coach.

The regular coaching sessions, through an app, help patients tackle chronic conditions through sustainable lifestyle and behaviour changes.

LWTC is a limited liability partnership between Birmingham-based social enterprise Health Exchange CIC and Exeter-based charity Westbank Community Health and Social Care.

Each organisation has expertise in supporting individuals to change their lives by establishing new patterns of behaviour to improve their health and wellbeing.

The LWTC programme consists of 13 sessions across nine months.

They cover key topics such as understanding the risks of diabetes, behaviour change techniques, healthy lifestyles and mental wellbeing.

Rune Bech, co-founder and UK head of Liva Healthcare, said: We are seeing remarkable results from people going through Livas programme.

"Patients with chronic conditions like obesity, pre-diabetes or type two diabetes have been able to halt or even reverse their conditions simply by providing personal health coaching.

This unique relationship-based approach makes hard-won lifestyle changes long lasting and sustainable.

"By providing a digital solution, the Liva programme is scalable and cost-effective and supports health professionals to drive real change in their communities.

"This new partnership with the NHS and LWTC will help us help even more people live longer and better, which is why we go to work every morning.

Russell Muirhead, clinical director for LWTC said: Were pleased to be named as an NHS Diabetes Prevention Programme provider across Shropshire, Telford and Wrekin.

"Were now busy working in partnership with the local health economy to meet the needs of the local communities from day one.

"This is vital given that over 11,000 people across Shropshire, Telford and Wrekin are at high risk of developing type two diabetes.

"Our focus remains on recruiting passionate local coaches who care about their communities and making a real difference to peoples lives.

Read the original:
Organisations partner with Shropshire health groups to prevent type two diabetes - shropshirestar.com

Read More...

Global diabetic footwear market is projected to reach $ 9.7 billion by 2025 – GlobeNewswire

Saturday, March 7th, 2020

New York, March 06, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Diabetic Footwear Market, By Product, By End User, By Distribution Channel, By Region, Competition, Forecast & Opportunities, 2025" - https://www.reportlinker.com/p05872172/?utm_source=GNW

Global diabetic footwear market is projected to reach $ 9.7 billion by 2025 on account of rising adoption of diabetic footwear as they are designed to minimize the risk of skin breakdown caused by poor circulation, neuropathy and foot deformities. Moreover, these footwears offer a variety of features like non-binding uppers, stretchable uppers, orthotic support, extra depth design for a pressure-free fit, deep-toe-box, functional soles, and others in order to protect diabetic feet. These designed footwears are mostly used by athletes and common people that are suffering from foot deformities caused by diabetes. Diabetes leads to poor control over blood sugar levels and thus can damage nerves and vessels of feet. Therefore, consumers with diabetes are more likely to have foot problems which are the key factor anticipated to influence the demand for diabetic footwear across the globe in the coming years. Rising prevalence of diabetes and growing disposable income are some of the major factors anticipated to propel the global diabetic footwear market in the coming years. However, the market growth is likely to be negatively affected on account of lack of proper knowledge about using diabetic footwear among potential users as well as low awareness about proper foot care in diabetic patients, particularly in underdeveloped and developing countries. The global diabetic footwear market is segmented based on the product, end-user, distribution channel and region.Based on the product, the market can be segmented into slippers, sandals and shoes.

Among them, the shoe footwear type dominated the market in 2019, and the product segment is expected to maintain its leadership position in the coming years as well which can be attributed to the higher preference of shoes in both men and women. Office going population always prefers wearing shoes since a formal attire includes shoe, which is increasing the demand for these shoes, thereby boosting the growth of this segment in the market. Major players operating in the diabetic footwear market are Podartis S.r.l., American Aetrex Worldwide, Inc., Orthofeet Inc, Drew Shoes (U.S.), Dr. Comfort, DJO Global Inc (U.S.), Dr. Zen Products, Inc. (U.S.), Propet USA, Inc. (U.S.), DARCO International, I-Runner (U.S.), Finn Comfort (U.S.), Pilgrim shoes (U.S.), Hush Puppies Retail, Inc., New Balance, Inc., and others.

Years considered for this report:

Historical Years: 2015-2018 Base Year: 2018 Estimated Year: 2019 Forecast Period: 20202025

Objective of the Study:

To analyze and forecast the market size of the global diabetic footwear market. To classify and forecast global diabetic footwear market based on the product, end-user, distribution channel, company and regional distribution. To identify drivers and challenges for the global diabetic footwear market. To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the global diabetic footwear market. To conduct a pricing analysis for the global diabetic footwear market. To identify and analyze the profile of leading players operating in the global diabetic footwear market. The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of diabetic footwear manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the manufacturers which could not be identified due to the limitations of secondary research. The analyst examined the distribution channels and presence of all major players across the globe. The analyst calculated the market size of global diabetic footwear market by using a bottom-up approach, wherein data for various end-user segments were recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Diabetic footwear manufacturers, suppliers and other stakeholders Government bodies such as regulating authorities and policymakers Organizations, forums and alliances related to diabetic footwear Market research and consulting firms The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, the global diabetic footwear market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: Market, By Product: o Shoes o Sandals o Slippers Market, By End User: o Men o Women Market, By Distribution Channel: o Store-based o Non-store based Market, By Region: o North America United States Mexico Canada o Asia-Pacific China Japan India South Korea Australia o Europe Germany France United Kingdom Italy Spain o South America Brazil Colombia Argentina o Middle East & Africa South Africa Saudi Arabia UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global diabetic footwear market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).Read the full report: https://www.reportlinker.com/p05872172/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
Global diabetic footwear market is projected to reach $ 9.7 billion by 2025 - GlobeNewswire

Read More...

Here is why Tandem Diabetes Care, Inc. (TNDM) stock volatility recorded over the last month was 5.48% – The InvestChronicle

Saturday, March 7th, 2020

Tandem Diabetes Care, Inc. (TNDM) is priced at $75.44 after the most recent trading session. At the very opening of the session, the stock price was $75.43 and reached a high price of $76.81, prior to closing the session it reached the value of $77.58. The stock touched a low price of $72.92.

Tandem Diabetes Care, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $91.65 on 02/20/20, with the lowest value was $51.37 for the same time period, recorded on 04/18/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Tandem Diabetes Care, Inc. shares are logging -17.69% during the 52-week period from high price, and 46.86% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $51.37 and $91.65.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 948399 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Tandem Diabetes Care, Inc. (TNDM) recorded performance in the market was 26.56%, having the revenues showcasing 18.36% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.53B, as it employees total of 1043 workers.

During the last month, 9 analysts gave the Tandem Diabetes Care, Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 67.89, with a change in the price was noted +18.90. In a similar fashion, Tandem Diabetes Care, Inc. posted a movement of +33.43% for the period of last 100 days, recording 1,545,246 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for TNDM is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Tandem Diabetes Care, Inc. in the period of last 50 days is set at 51.19%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 20.97%. In the last 20 days, the companys Stochastic %K was 32.85% and its Stochastic %D was recorded 35.90%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 26.56%. Additionally, trading for the stock in the period of the last six months notably improved by 7.83%, alongside a boost of 22.11% for the period of the last 12 months. The shares increased approximately by 7.84% in the 7-day charts and went down by 1.04% in the period of the last 30 days. Common stock shares were driven by 18.36% during last recorded quarter.

Continue reading here:
Here is why Tandem Diabetes Care, Inc. (TNDM) stock volatility recorded over the last month was 5.48% - The InvestChronicle

Read More...

Frequent Tooth Brushing Tied to Lower Diabetes Risk – The New York Times

Friday, March 6th, 2020

Brushing your teeth frequently may reduce your risk for diabetes, new research suggests.

Using Korean government health records and self-reports, researchers gathered health and behavioral data on 188,013 men and women, average age 53, who were free from diabetes. More than 17 percent had periodontal disease. Over the course of the 10-year study, 31,545 developed diabetes.

After controlling for age, sex, socioeconomic status, smoking, alcohol consumption, physical activity, lipid levels, hypertension and other factors, they found that people with periodontal disease had a 9 percent increased risk for developing diabetes. The study is in Diabetologia.

Compared with people who did not brush or brushed only once a day, those who brushed twice a day had a 3 percent reduced risk for diabetes, and those who brushed three times a day an 8 percent reduced risk. The loss of 15 or more teeth was associated with a 21 percent increased risk for developing diabetes.

Neither the number of visits to the dentist or the frequency of professional tooth cleaning was associated with the incidence of diabetes.

The lead author, Dr. Yoonkyung Chang, a professor of neurology at Ewha Womans University in Seoul, said that healthy lifestyle has more powerful effects on diabetes prevention than tooth brushing.

But, she said, Frequent tooth brushing reduces local inflammation and bacteremia, and if good brushing habits persist for a long time, this can affect systemic diseases.

The rest is here:
Frequent Tooth Brushing Tied to Lower Diabetes Risk - The New York Times

Read More...

News Diabetes Prevention Program to be Offered Soon – Bartlesville Radio

Friday, March 6th, 2020

Ascension St. John Jane Phillips in Bartlesville will present Diabetes Prevention Program, a year-long class, led by certified lifestyle coaches at the end of the month.

Sessions will be weekly March 25th through July 1dt from 5:00 to 6:00 p.m., then monthly for the year. Cost is $5 per month. For questions or more information, call 918.331.1143.

Classes are held at the Medical Park Center, 3400 SE Frank Phillips Blvd., Suite 200 in the Ascension St. John Jane Phillips Diabetes and Nutrition Education classroom.

Prediabetes is a serious health condition where blood sugar levels are higher than normal, but not high enough yet to be diagnosed as type 2 diabetes. Over 88 million American adults have prediabetes thats 1 in 3 adults. Of those 88 million, more than 8 in 10 of them dont even know they have it. Without taking action, many people with prediabetes could develop type 2 diabetes within 5 years.

Diabetes is a serious disease that can cause heart attack, stroke, blindness, kidney failure, or loss of feet or legs.

The good news is Type 2 diabetes can be delayed or prevented in people with prediabetes through effective lifestyle programs. With modest lifestyle changes including healthy eating and increased physical activity men and women can decrease the likelihood of developing Type 2 diabetes.

Go here to read the rest:
News Diabetes Prevention Program to be Offered Soon - Bartlesville Radio

Read More...

Coronavirus and Diabetes: What You Need to Know by Johanna Hicks, Family & Community Health Agent – frontporchnewstexas.com

Friday, March 6th, 2020

Coronavirus and Diabetes: What You Need to Know

Unless youve been living under a rock the past few weeks, you have heard of a new and deadly virus that has quickly been spreading around the world: Coronavirus, or COVID-19, which is a highly infectious, acute respiratory disease. This disease only affects mammals and birds, and seems to have originated from a seafood market in the Wuhan Province of China. The numbers are changing daily, but the most recent numbers show that over 76,000 people have been infected with the virus, with 99% of them occurring within mainland China.

Because diabetes education is my passion, I wanted to share some information from author Christine Fallabel, Diabetes Daily. So how dangerous is the Coronavirus, and what do you need to know as a person living with diabetes? Many people who are infected with the virus never seek treatment. According to the World Health Organization, signs of the infection include fever, cough, shortness of breath, and difficulty breathing. If you suspect you may be infected, see your doctor right away.

To protect yourself from getting any type of seasonal virus, its best to avoid contact with other sick people, wash your hands frequently (especially and always after using the restroom and before preparing food!), wear a protective mask when traveling through airports or busy bus/train stations, get your flu vaccination, maintain a healthy sleep schedule, and eat plenty of fruits and vegetables. According to the CDC, Coronavirus is spread by respiratory droplets in the air when an infected person sneezes or coughs. The virus can also be spread when an uninfected person touches a surface where the virus is (bathroom countertops or door handles), and then touches their face or mouth. Carrying antimicrobial hand sanitizer with you can help to eliminate this threat.

Sometimes your diabetes gives clues when youre starting to get sick, and one of those clues is higher-than-normal blood sugars. If youre starting to see your numbers creep up for no reason, it could be a sign that youre coming down with something. Stay on top of your diabetes when you get ill. This will include more frequent blood glucose testing, staying hydrated, checking ketones, and if on insulin, might require extra dosages.

Even though most cases are mild, having a chronic illness and a virus at the same time can cause major trouble. Seek help from a physician if you suspect something is beyond your control. Even though we are not in crisis mode concerning the Coronavirus in the United States, always be prepared with extra diabetes supplies lancets, test strips, medications. The main goal is to be proactive in protecting yourself and being aware of how your body responds.

Do Well, Be Well with Diabetes Series

Have you been diagnosed with diabetes and dont know what to do next? Are you afraid of complications? Are you confused about which foods spike your blood glucose? Do you know what your blood glucose ranges should be? Are you wondering what a hemoglobin A1c is and what yours should be?

All of these questions and concerns will be answered in this informative series! Pharmacists, diabetes specialists, and more will be on hand to lead the sessions and allow you to interact, ask questions, and share experiences. You still have time to sign up by calling the Texas A&M AgriLife Extension Office in Sulphur Springs at 903-885-3443. Topics to be covered include glucose monitoring, nutrition/meal planning, sick day management, medications, role of physical activity, delaying/preventing complications, or if you already have complications, how to manage them.

Cost is only $25 for the entire series, payable at the first session and includes materials, refreshments, and a chance for door prizes. Sessions will take place at the Hopkins County Extension Office on Mondays and Thursdays, March 9. 12. 16. 19, and 23.

Closing Thought

No life ever grows great until it is focused, dedicated, and disciplined unknown

Article by Johanna Hicks,Texas A&M AgriLife Extension,Family & Community Health Agent

Originally posted here:
Coronavirus and Diabetes: What You Need to Know by Johanna Hicks, Family & Community Health Agent - frontporchnewstexas.com

Read More...

Evening Lions present diabetic kits to local schools – Great Bend Tribune

Friday, March 6th, 2020

Diabetes is the signature cause of Lions clubs around the world, as well as right here in Barton County. The Great Bend Evening Lions Club last week presented diabetic emergency kits to area schools.

In all, 14 of the kits went to schools in Great Bend and four to schools in Hoisington, said club member and project organizer Stan Jantz. These are for nurses or students to use.

The kits include snacks and other items for students with blood sugar issues or in some other form of diabetic distress, he said. However, they do not include insulin or other medications.

Approximately 293,860 people in Kansas, or 12.6% of the adult population, have diabetes, according to the American Diabetes Association. Of these, an estimated 69,000 have diabetes but dont know it, greatly increasing their health risk.

Nationally, 30.3 million people, or 9.4% of the U.S. population, have diabetes, the ADA notes. An estimated 23.1 million people, or 7.2% of the population, have been diagnosed with diabetes.

But, this is also a global issue. Lions Club International has partnered with the International Diabetes Federation to fight this disease.

In March 2018, Lions Clubs International and the International Diabetes Federation signed a memorandum of understanding, on the occasion of Lions Day at the UN, to establish a cooperative alliance in the global fight against diabetes.

The two organizations came together to help prevent diabetes and improve the quality of life for those living with diabetes worldwide, a joint statement reads.

According to the IDF, In 2019:

Approximately 463 million adults (20-79 years) were living with diabetes; by 2045 this will rise to 700 million.

The proportion of people with type 2 diabetes is increasing in most countries.

79% of adults with diabetes were living in low- and middle-income countries.

1 in 5 of the people who are above 65 years old have diabetes.

1 in 2 (232 million) people with diabetes were undiagnosed.

Diabetes caused 4.2 million deaths.

Diabetes caused at least USD 760 billion dollars in health expenditure in 2019 10% of total spending on adults.

More than 1.1 million children and adolescents are living with type 1 diabetes.

More than 20 million live births (1 in 6 live births) are affected by diabetes during pregnancy.

374 million people are at increased risk of developing type 2 diabetes.

View original post here:
Evening Lions present diabetic kits to local schools - Great Bend Tribune

Read More...

Study Suggests Guidelines to Improve YouTube Video Content for Patients with Diabetes and Other Chronic Health Conditions – DocWire News

Friday, March 6th, 2020

The findings of a study suggest that health care providers and organizations should follow a set of guidelines for producing engaging, easily digestible YouTube content that helps patients with chronic health conditions, such as diabetes, managing their diagnoses.

The researchers specifically focused on how users engage with medical information on diabetes because it stands as one of the most prevalent chronic conditions in the US.

The study, conducted by researchers at Carnegie Mellon University, the University of Utah, the University of Arizona, and Michigan State University, was published in the journalMIS Quarterly.

To conduct this study, the researchers used over 200 search terms to compile a list of 19,873 unique YouTube videos that were uploaded by individual users as well health care organizations, such as Mayo Clinic, the American Diabetes Association, and the American Nutrition Association. Next, they used a deep learning method to identify medical terms found in videos before grouping videos based on how much medical information they contained. They also focused on different ways these videos presented information, via text and images. Subsequently, the researchers assessed the data to determine how viewers collectively paid attention to the videos in different ways.

According to the results of the study, viewers who watched YouTube videos that contained limited medical information (e.g. videos filled with unsubstantial claims or excessive ads) typically did not engage with the videos, suggesting the need for medical content. However, the study also found that viewers who watched YouTube videos saturated with medical terms also struggled to maintain attention. The authors noted that considering the low levels of health literacy in the US, viewers may become intimidated by seeing an abundance of medical terminology.

Our study helps health care practitioners and policymakers understand how users engage with medical information in video format, says study co-author Rema Padman, professor of management science and healthcare informatics at Carnegie Mellon Universitys Heinz College in a press release. It also contributes to enhancing current public health practices by promoting the development of guidelines for the content of educational videos that aim to help people cope with chronic conditions.

Based on their findings, the researchers suggest that specific guidelines should be developed for individuals and organizations that produce YouTube content so they can provide engaging and relevant material to patients with chronic conditions. They recommend using automated video retrieval a method which identifies, and labels videos based on their level of content to accommodate patients varying levels of comprehending medical information.

As organizations produce health-related educational materials for patients, they should think not only about what medical information to deliver, but also how to meet the interest, information needs, and health-literacy levels of the consumers, Prof. Padman suggests. Creators of these materials should use technology and online solutions to reach patients with complex chronic conditions with personalized, contextualized, and just-in-time content.

Originally posted here:
Study Suggests Guidelines to Improve YouTube Video Content for Patients with Diabetes and Other Chronic Health Conditions - DocWire News

Read More...

Payer Effects of Personalized Preventive Care for Patients With Diabetes – AJMC.com Managed Markets Network

Friday, March 6th, 2020

Brant Morefield, PhD; Lisa Tomai, MS; Vladislav Slanchev, PhD; and Andrea Klemes, DO

We examine the effects of MDValue in Prevention (MDVIP) enrollment on Medicare expenditures and utilization among fee-for-service beneficiaries with diabetes over a 5-year period.

Objectives:

Study Design: We obtained participating physician and beneficiary enrollment lists from MDVIP and Medicare FFS claims data through the Virtual Research Data Center to compare changes in outcomes, before and after enrollment dates, with those of nonenrolled beneficiaries receiving primary care in the same local market.

Methods: We employed propensity score matching to identify comparison beneficiaries similar in observed characteristics and preenrollment trends. Individual fixed effects were used to control for time-consistent differences between treatment and comparison populations.

Results: We found that enrollment is statistically associated with reductions in outpatient expenditures, Medicare expenditures in year 5, emergency department (ED) utilization, and unplanned inpatient admissions, accompanied by significant increases in evaluation and management visits and expenditures. Total Medicare expenditures over the 5-year period, as well as all inpatient admissions, were not statistically different between the MDVIP and comparison groups.

Conclusions: Our finding of reduced unplanned inpatient admissions and ED utilization supports the previous findings regarding MDVIP enrollees. We did not find significant changes in overall third-party expenditures, although savings were estimated in year 5, the last year of observation, and may occur later. Our approach, however, strengthens controls for baseline characteristics of the population and uses a comparison population drawn from the same markets who do not experience the loss of their primary care physician at the time of enrollment.

Am J Manag Care. 2020;26(3):In Press

We used claims data to examine how healthcare utilization and third-party Medicare expenditures change after individuals with diabetes enroll in the MDValue in Prevention (MDVIP) model.

Prior research suggests that enrollment in MDVIP reduces utilization of inpatient or emergency department (ED) services. Musich et al analyzed medical utilization of MDVIP members in comparison with a sample of Medicare Advantage beneficiaries who did not join the model and showed that participation in MDVIP led to savings in medical expenditures for 2 years after joining, resulting from reduced hospitalizations and ED visits.3 Similar reductions in healthcare utilization related to MDVIP membership were found by Klemes et al4 and Musich et al,5 who used patient-level data from 5 states within the Intellimed data set and a sample of patients with a UnitedHealthcare employer-sponsored health plan, respectively. Our study continues this evidence base by examining the role of the MDVIP model on third-party Medicare fee-for-service (FFS) expenditures and healthcare utilization for the older Medicare FFS population. Further, we chose to focus on a population with diabetes, a common and costly chronic condition, because patients with chronic conditions may experience differential effects of personalized primary care arrangements from those presented in prior research.

As physician and patient participation is voluntary and involves enrollment fees for patients, we expect that MDVIP physicians and patients may differ from others who are part of the Medicare FFS population. A review of the work of Klemes et al4 by the American College of Physicians raised questions regarding identification of an MDVIP effect without further adjustment for baseline health and socioeconomic factors.6 We addressed such factors in this study by matching comparison beneficiaries on observed characteristics, including baseline health, and controlling for time-consistent unobserved characteristics using fixed effects.

METHODS

We obtained lists of MDVIP-participating physicians and MDVIP-enrolled beneficiaries 65 years or older, as well as their associated program enrollment dates, from MDVIP, and 2000-2015 Medicare claims (parts A and B) and Master Beneficiary Summary File Chronic Conditions segment data from the Virtual Research Data Center. The Chronic Conditions segment applies algorithms to identify the incidence of chronic conditions based on diagnosis and service codes in beneficiaries claims histories. We used these chronic condition flags to identify beneficiaries meeting the diabetic criteria at the time of MDVIP enrollment or potential enrollment.

Study Populations

We first identified all Medicare FFS beneficiaries receiving at least 1 Part B service from an MDVIP-affiliated physician in a 15-month period ending when the physician joined MDVIP, including both beneficiaries who did and did not join the MDVIP model. Among beneficiaries receiving care from future MDVIP-affiliated physicians, we cross-referenced sex, date of birth, and zip code in Medicare records with MDVIP enrollment files. Using this approach, we uniquely identified 90% of FFS beneficiaries listed by MDVIP.

We also identified unaffiliated primary care physicians operating in the same primary care service area (PCSA) and the population of patients receiving care from these non-MDVIP physicians in the 15 months prior to when the MDVIP physicians joined. As such, we selected a population of potential comparison beneficiaries who received primary care in the same market at the same time as beneficiaries who enroll in MDVIP, where markets are defined as PCSAs.7

Because more than 90% of beneficiaries enrolled in MDVIP within 30 days of their providers enrollment, and 95% within 90 days, we used the providers enrollment dates as the start of MDVIP for the enrolled population. For beneficiaries seeing non-MDVIP providers, the intervention start date was defined as the enrollment date of the linked local MDVIP provider.

From the providers enrollment dates, we extracted beneficiaries Medicare FFS claims 3 years prior to and up to 5 years post enrollment. We only included years in which the beneficiary was enrolled in Medicare Part A and Part B and not enrolled in Medicare managed care.

Go here to see the original:
Payer Effects of Personalized Preventive Care for Patients With Diabetes - AJMC.com Managed Markets Network

Read More...

Page 30«..1020..29303132..4050..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick